Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

A. Iacobellis, M. Siciliano, B. E. Annicchiarico, M. R. Valvano, G. A. Niro, L. Accadia, N. Caruso, G. Bombardieri, A. Andriulli

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background Little data is available about predictors of sustained virological response (SVR) during anti-viral therapy of patients with decompensated HCV cirrhosis. Aims To determine whether rapid and early virological responses (RVR and EVR) could predict SVR and help optimize treatment in these patients. Methods A total of 94 cirrhotics underwent treatment with peg-interferon alfa-2b (1.5 g/kg weekly) and ribavirin (800/1200 mg daily) for 48 or 24 weeks for genotypes 1/4 or genotypes 2/3, respectively. Results Overall, SVR was achieved in 33 patients (35.1%), 16% with genotype 1/4 and 56.8% with genotype 2/3 (P <0.01). At treatment week 4, 34 patients had undetectable HCV-RNA, 10 with genotype 1/4 and 24 with genotype 2/3. Of RVR patients, 24 achieved SVR (70.5%), 6 and 18 with genotypes 1 and non-1. At the multivariate analysis, only EVR, genotypes 2 and 3, and adherence to full course and dosage of therapy retained their independent predictive power, with corresponding ORs of 25.5 (95% CI 3.0-217.3), 4.2 (95% CI 1.2-15.3) and 9.1 (95% CI 2.2-38.0), respectively. Conclusion In decompensated cirrhotic patients, anti-viral therapy with current regimens is feasible and associated with an overall SVR rate of 35.1%. Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy.

Original languageEnglish
Pages (from-to)146-153
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume30
Issue number2
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Genotype
interferon alfa-2b
Therapeutics
Ribavirin
Fibrosis
Multivariate Analysis
RNA

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. / Iacobellis, A.; Siciliano, M.; Annicchiarico, B. E.; Valvano, M. R.; Niro, G. A.; Accadia, L.; Caruso, N.; Bombardieri, G.; Andriulli, A.

In: Alimentary Pharmacology and Therapeutics, Vol. 30, No. 2, 07.2009, p. 146-153.

Research output: Contribution to journalArticle

Iacobellis, A. ; Siciliano, M. ; Annicchiarico, B. E. ; Valvano, M. R. ; Niro, G. A. ; Accadia, L. ; Caruso, N. ; Bombardieri, G. ; Andriulli, A. / Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. In: Alimentary Pharmacology and Therapeutics. 2009 ; Vol. 30, No. 2. pp. 146-153.
@article{e50413edc9d542dbacb8f42b84626af5,
title = "Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients",
abstract = "Background Little data is available about predictors of sustained virological response (SVR) during anti-viral therapy of patients with decompensated HCV cirrhosis. Aims To determine whether rapid and early virological responses (RVR and EVR) could predict SVR and help optimize treatment in these patients. Methods A total of 94 cirrhotics underwent treatment with peg-interferon alfa-2b (1.5 g/kg weekly) and ribavirin (800/1200 mg daily) for 48 or 24 weeks for genotypes 1/4 or genotypes 2/3, respectively. Results Overall, SVR was achieved in 33 patients (35.1{\%}), 16{\%} with genotype 1/4 and 56.8{\%} with genotype 2/3 (P <0.01). At treatment week 4, 34 patients had undetectable HCV-RNA, 10 with genotype 1/4 and 24 with genotype 2/3. Of RVR patients, 24 achieved SVR (70.5{\%}), 6 and 18 with genotypes 1 and non-1. At the multivariate analysis, only EVR, genotypes 2 and 3, and adherence to full course and dosage of therapy retained their independent predictive power, with corresponding ORs of 25.5 (95{\%} CI 3.0-217.3), 4.2 (95{\%} CI 1.2-15.3) and 9.1 (95{\%} CI 2.2-38.0), respectively. Conclusion In decompensated cirrhotic patients, anti-viral therapy with current regimens is feasible and associated with an overall SVR rate of 35.1{\%}. Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy.",
author = "A. Iacobellis and M. Siciliano and Annicchiarico, {B. E.} and Valvano, {M. R.} and Niro, {G. A.} and L. Accadia and N. Caruso and G. Bombardieri and A. Andriulli",
year = "2009",
month = "7",
doi = "10.1111/j.1365-2036.2009.04025.x",
language = "English",
volume = "30",
pages = "146--153",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

AU - Iacobellis, A.

AU - Siciliano, M.

AU - Annicchiarico, B. E.

AU - Valvano, M. R.

AU - Niro, G. A.

AU - Accadia, L.

AU - Caruso, N.

AU - Bombardieri, G.

AU - Andriulli, A.

PY - 2009/7

Y1 - 2009/7

N2 - Background Little data is available about predictors of sustained virological response (SVR) during anti-viral therapy of patients with decompensated HCV cirrhosis. Aims To determine whether rapid and early virological responses (RVR and EVR) could predict SVR and help optimize treatment in these patients. Methods A total of 94 cirrhotics underwent treatment with peg-interferon alfa-2b (1.5 g/kg weekly) and ribavirin (800/1200 mg daily) for 48 or 24 weeks for genotypes 1/4 or genotypes 2/3, respectively. Results Overall, SVR was achieved in 33 patients (35.1%), 16% with genotype 1/4 and 56.8% with genotype 2/3 (P <0.01). At treatment week 4, 34 patients had undetectable HCV-RNA, 10 with genotype 1/4 and 24 with genotype 2/3. Of RVR patients, 24 achieved SVR (70.5%), 6 and 18 with genotypes 1 and non-1. At the multivariate analysis, only EVR, genotypes 2 and 3, and adherence to full course and dosage of therapy retained their independent predictive power, with corresponding ORs of 25.5 (95% CI 3.0-217.3), 4.2 (95% CI 1.2-15.3) and 9.1 (95% CI 2.2-38.0), respectively. Conclusion In decompensated cirrhotic patients, anti-viral therapy with current regimens is feasible and associated with an overall SVR rate of 35.1%. Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy.

AB - Background Little data is available about predictors of sustained virological response (SVR) during anti-viral therapy of patients with decompensated HCV cirrhosis. Aims To determine whether rapid and early virological responses (RVR and EVR) could predict SVR and help optimize treatment in these patients. Methods A total of 94 cirrhotics underwent treatment with peg-interferon alfa-2b (1.5 g/kg weekly) and ribavirin (800/1200 mg daily) for 48 or 24 weeks for genotypes 1/4 or genotypes 2/3, respectively. Results Overall, SVR was achieved in 33 patients (35.1%), 16% with genotype 1/4 and 56.8% with genotype 2/3 (P <0.01). At treatment week 4, 34 patients had undetectable HCV-RNA, 10 with genotype 1/4 and 24 with genotype 2/3. Of RVR patients, 24 achieved SVR (70.5%), 6 and 18 with genotypes 1 and non-1. At the multivariate analysis, only EVR, genotypes 2 and 3, and adherence to full course and dosage of therapy retained their independent predictive power, with corresponding ORs of 25.5 (95% CI 3.0-217.3), 4.2 (95% CI 1.2-15.3) and 9.1 (95% CI 2.2-38.0), respectively. Conclusion In decompensated cirrhotic patients, anti-viral therapy with current regimens is feasible and associated with an overall SVR rate of 35.1%. Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy.

UR - http://www.scopus.com/inward/record.url?scp=67649880240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649880240&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.04025.x

DO - 10.1111/j.1365-2036.2009.04025.x

M3 - Article

VL - 30

SP - 146

EP - 153

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -